

Patent claims

- 5 1. Directly compressible tableting aid characterized in that it has a xylitol content of more than 90% by weight and a content of at least one other polyol of less than 10% by weight, and is produced by spray drying or fluidized bed granulation.
- 10 2. Directly compressible tableting aid according to Claim 1, characterized in that the other polyols present in addition to xylitol are selected from the group consisting of mannitol and lactitol.
- 15 3. *Claim 1* Directly compressible tableting aid according to ~~either of Claims 1 or 2~~, characterized in that it is obtainable by dissolving xylitol and at least one other polyol in water and spraying the resulting aqueous mixture in a stream of air at a temperature of from 120°C to 300°C.
- 20 4. *Claim 1* Directly compressible tableting aid according to ~~either of Claims 1 or 2~~, characterized in that it is obtainable by dissolving xylitol and at least one other polyol in water and fluidizing the resulting aqueous mixture in a stream of air at a temperature of from 30°C to 110°C.
- 25 5. *Claim 1* Directly compressible tableting aid according to ~~any of Claims 1 to 4~~, characterized in that xylitol and mannitol, xylitol and lactitol or xylitol, mannitol and lactitol are employed as polyols.
- 30 6. Directly compressible tableting aid according to Claim 5, characterized in that the ratio of xylitol to mannitol is in a range between 90:10 to 98:2, in particular between 90:10 to 95:5.
- 35 7. Directly compressible tableting aid according to Claim 5, characterized in that the ratio of xylitol to lactitol is in a range between 90:10 to 98:2, in particular between 90:10 to 95:5.
8. Directly compressible tableting aid according to Claim 5, characterized in that the xylitol:mannitol:lactitol ratio is in a range between 90:1:9 or 90:9:1 and 98:1:1.

004440 "CHS62560

9. Claim 1 Directly compressible tabletting aid according to any of ~~Claims 1 to 8~~, characterized in that the water content is less than 1% by weight.

10. Process for producing a directly compressible tabletting aid according to any ^{new} of Claims 1 to 9, objection characterized in that it comprises the following steps:

10 a) producing an aqueous solution of xylitol and at least one other polyol, the resulting mixture having a xylitol content of more than 90% by weight based on the total polyol content,

b1) spraying the resulting mixture in a stream of air at a temperature of from 120°C to 300°C, evaporation of the water taking place,

15 b2) fluidizing the resulting mixture in a stream of air at a temperature of from 30°C to 110°C, evaporation of the water taking place, and

c) isolating the tabletting aid.

20 10/ 11. Use of a directly compressible tabletting aid according to any of Claims 1 to 9 for producing shaped and unshaped polyol compositions by melt extrusion.

12. Compositions or formulations, characterized in that they comprise a directly compressible tabletting aid according to any of Claims 1 to 9.

25 13. Solid forms or compacts, characterized in that they comprise a directly compressible tabletting aid according to any of Claims 1 to 9.

14. Solid forms or compacts according to Claim 13, characterized in that they comprise one or more water-insoluble and/or water-soluble additions homogeneously dispersed.

30 15. Claim 13 Solid forms or compacts according to ~~either of Claims 13 or 14~~, characterized in that they comprise citric acid as addition.

35 16. Claim 13 Solid forms or compacts according to any of Claims 13 to 15, characterized in that they comprise one or more additions selected from the group of active pharmaceutical ingredients, sweeteners, colorants, vitamins and trace elements.

0044140-4456560

17. Solid forms or compacts according to Claim 16, characterized in that they comprise one or more active pharmaceutical ingredients selected from the group of analgesics and antacids. ¹¹²

5 18. Solid forms or compacts according to Claim 16, characterized in that they comprise one or more sweeteners selected from the group of acesulfame K, aspartame, saccharin, cyclamate, ¹¹² sucralose and neohesperidine DC.

add
C1

add
C1

004440-044400